Page 13 - Bharat Biotech
Covid: Committed to data transparency on Covaxin, says Bharat Biotech
Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent, and the company has so far published nine research studies on its safety and efficacy. "Covaxin's scientific standards+commitment is transparent. Academic journals, peer reviewers, NIV-ICMR-BB researchers -scientists,9 studys & data published," BharatBiotech CoFounder & Joint MD Suchitra Ella said in a tweet. The complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India, Bharat Biotech said in a statement. "In a timely approach to peer review, the company has already published as many as nine research studies on the safety and efficacy of Covaxin in five globally reputed peer-reviewed journals in a span of just twelve months," it added. Covaxin, a whole-virion inactivated coronavirus vaccine, is the first and only product to have published any data from ...
 "Covid: Committed to data transparency on Covaxin, says Bharat Biotech")
Covid-19 pandemic: Bharat Biotech's Covaxin set for clinical trials in US
FDA asks Bharat Bio's US partner Ocugen to apply for full authorisation
 "Covid-19 pandemic: Bharat Biotech's Covaxin set for clinical trials in US")
Bharat Biotech to conduct additional clinical trials for USFDA nod
Timelines will be delayed; firm has received EUSs from 14 other countries
FDA denies Bharat Bio's US partner emergency approval for Covaxin vaccine
US FDA has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application route with additional data, nixinghopes of Emergency Use Authorisation
 "FDA denies Bharat Bio's US partner emergency approval for Covaxin vaccine")
Top Headlines: Pfizer Covid vax's 'India price', Twitter India seeks a week
Business Standard brings top headlines on Thursday
 "Top Headlines: Pfizer Covid vax's 'India price', Twitter India seeks a week")
Covaxin Phase-3 efficacy analysis to be made public by July: Bharat Biotech
The company is also doing phase-4 trials for real world effectiveness of the jab
Bharat Biotech expects peer review of Covaxin's Phase 3 trials data in Q4
Bharat Biotech is yet to publish the data of Covaxin's phase-3 trial
 "Bharat Biotech expects peer review of Covaxin's Phase 3 trials data in Q4")
Centre fixes maximum price for Covid-19 vaccines at private hospitals
The CoWIN system would also ensure that the prices declared by various private vaccination centres do not exceed the maximum price
 "Centre fixes maximum price for Covid-19 vaccines at private hospitals")
Covid-19 vaccination: Govt books 440 million doses with 30% advance
250 mn Covishield and 190 mn Covaxin doses meant for Aug-Dec period
 "Covid-19 vaccination: Govt books 440 million doses with 30% advance")
Study on Covishield, Covaxin antibody response is limited: Bharat Biotech
Raches Ella, project lead, Covid-19 vaccines at the firm says he is surprised that media and researchers are drawing conclusions based on non-peer reviewed work
 "Study on Covishield, Covaxin antibody response is limited: Bharat Biotech")
Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals
The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145
Covid-19 vaccine manufacturers, private hospitals face revenue loss
Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month
Free Covid-19 vaccine for all above 18 years from June 21: PM Modi
Of the total vaccine availability, 75 per cent will be procured by the Centre and the remaining 25 per cent will continue to be available for private hospitals.
 "Free Covid-19 vaccine for all above 18 years from June 21: PM Modi")
Covishield shows better antibody response than Covaxin, says study
The study was aimed at analysing the antibody response after two complete doses of Covishield and Covaxin in Indians
Do not politicise GST Council: Finance Minister Nirmala Sitharaman
The government is conscious of the intensity of the second wave of Covid-19 and is assessing its full impact before coming out with further packages and interventions, says FM Sitharaman
 "Do not politicise GST Council: Finance Minister Nirmala Sitharaman")
Bharat Biotech, Ocugen extend agreement to market Covaxin in Canada
Phase 3 analysis data to be submitted to WHO soon for EUL
Decoded: Who can get antibody cocktail for Covid-19 and how it works
Used to treat only mild to moderate disease in high-risk Covid-19 patients, doctors feel the treatment can bolster the fight against severe disease
 "Decoded: Who can get antibody cocktail for Covid-19 and how it works")
Bharat Biotech to ramp up production of Covaxin to 100-120 mn doses by July
There has been shortage of vaccines after it was decided to open up vaccination to all those above 18 years.
 "Bharat Biotech to ramp up production of Covaxin to 100-120 mn doses by July")
World should learn the right lessons from India's Covid-19 cataclysm
All nations should now understand that vaccines work and that interfering with their supply is dangerous.
 "World should learn the right lessons from India's Covid-19 cataclysm")
Production of Covaxin is a complex, time-consuming process: Bharat Biotech
Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.